KNSA
$46.08+0.45 (+0.99%)
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.
Recent News
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Recent Share Price Pullback
Kiniksa Pharmaceuticals International (KNSA) has drawn investor attention after its recent trading session, with the stock closing at $45.15. The move comes against a backdrop of ongoing revenue and net income generation in biopharmaceutical therapies. See our latest analysis for Kiniksa Pharmaceuticals International. While the share price has eased, with a 1-day share price return showing a 3.98% decline and a 7-day share price return showing a 2.50% decline, the 1-year total shareholder...
Evommune Stock Sees RS Rating Rise To 91
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
KalVista Pharmaceuticals Stock Sees RS Rating Jump To 86
The Relative Strength (RS) Rating for KalVista Pharmaceuticals stock entered a new percentile Wednesday, with a rise from 79 to 86. Decades of market research shows that the best-performing stocks typically have an 80 or higher RS Rating as they begin their biggest price moves. Is KalVista Pharmaceuticals Stock A Buy?
Viking Therapeutics Stock Gets RS Rating Upgrade
Viking Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Xenon Pharmaceuticals Stock Sees RS Rating Rise To 77
Xenon Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating